Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 18, 2026, 1:20 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–8 of 8 matching trials from the live ClinicalTrials.gov search.
Conditions
Glioblastoma, Glioma
Interventions
GDC-0084
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
4
States / cities
Los Angeles, California • Boston, Massachusetts • Houston, Texas
Conditions
Glioblastoma
Interventions
Temozolomide, Lomustine, Regorafenib, Radiation, Paxalisib, VAL-083, VT1021, Troriluzole, ADI-PEG 20, AZD1390, Tinostamustine
Drug · Radiation · Biological
Lead sponsor
Global Coalition for Adaptive Research
Other
Eligibility
18 Years and older
Enrollment
2,250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
42
States / cities
Birmingham, Alabama • La Jolla, California • Los Angeles, California + 31 more
Conditions
Glioblastoma, Adult
Interventions
Paxalisib (GDC-0084)
Drug
Lead sponsor
Kazia Therapeutics Limited
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
6
States / cities
Los Angeles, California • Aurora, Colorado • Boston, Massachusetts + 3 more
Conditions
Breast Cancer
Interventions
Trastuzumab, GDC-0084
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Conditions
Brain and Central Nervous System Tumors
Interventions
GDC-0084, radiation therapy
Drug · Radiation
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
2 Years to 21 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Brain Metastases, Leptomeningeal Metastasis
Interventions
GDC-0084, whole brain radiation therapy radiation
Drug · Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
9
States / cities
Miami, Florida • Basking Ridge, New Jersey • Middletown, New Jersey + 6 more
Conditions
Primary Central Nervous System Lymphoma, Non-Hodgkin Lymphoma of Extranodal Site
Interventions
PAXALISIB
Drug
Lead sponsor
Lakshmi Nayak, MD
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Conditions
Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent Diffuse Intrinsic Pontine Glioma, Recurrent Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent WHO Grade III Glioma, WHO Grade III Glioma
Interventions
ONC201, Radiation Therapy, Paxalisib, DNX-2401
Drug · Radiation
Lead sponsor
University of California, San Francisco
Other
Eligibility
2 Years to 39 Years
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 16 more